Revenue of AbbVie's Humira 2011-2024

This statistic illustrates the revenue of pharmaceutical product Humira from 2011 to 2024. In 2024, AbbVie's top product generated **** billion U.S. dollars of revenue. Abbot Laboratories was a U.S.-based global pharmaceutical and healthcare products company, headquartered in Chicago, Illinois. In ************, Abbott was separated into two companies: Abbott and AbbVie. Abbott is now specialized on medical products, while AbbVie is responsible for research-based pharmaceuticals. On May 8, 2020, AbbVie completed the acquisition of Allergan plc. 

Abbvie's top product Humira

AbbVie’s Humira has increased its revenue from 2011 to 2022, generating *** billion U.S. dollars in 2011 and a record high of **** billion U.S. dollars in 2022. However, with generic versions of Humira entering the U.S. market in 2023, the revenue dropped dramatically by over ***** billion dollars. In the United States, 2019 was the year when AbbVie spent the highest amount of advertising for Humira. 

Adalimumab is marketed as Humira, a biotech pharmaceutical product. The name “Humira” is derived from “human monoclonal antibody in rheumatoid arthritis”. The inhibiting anti-inflammatory drug acts by inhibiting the activation of tumor necrosis factor-alpha (TNF) which can downregulate inflammation caused by autoimmune diseases. For example, it can be used for rheumatoid arthiritis which attacks the joints and can also impact tissues and organs. Humira can be also be used for diseases such as Plaque psoriasis and Crohn’s disease. Humira's price was a hot debated topic. The drug's price has effectively increased ** percent within the period of 2016-2021, the largest price increase among blockbuster drugs.